{"protocolSection": {"identificationModule": {"nctId": "NCT02033889", "orgStudyIdInfo": {"id": "8835-007"}, "secondaryIdInfos": [{"id": "2013-003290-95", "type": "EUDRACT_NUMBER"}, {"id": "B1521017", "type": "OTHER", "domain": "Pfizer Protocol Number"}, {"id": "MK-8835-007", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy."}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-12-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-08-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-08-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-01-09", "studyFirstSubmitQcDate": "2014-01-09", "studyFirstPostDateStruct": {"date": "2014-01-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-06-20", "resultsFirstSubmitQcDate": "2018-08-09", "resultsFirstPostDateStruct": {"date": "2018-09-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-09", "lastUpdatePostDateStruct": {"date": "2018-09-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo.", "detailedDescription": "The trial includes a 13-15 week run-in period prior to randomization, and a 26-week, double-blind, placebo-controlled treatment period followed by a 78-week double-blind, extension period."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 621, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ertuglifozin 5 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.", "interventionNames": ["Drug: Ertugliflozin 5 mg", "Drug: Placebo to Ertugliflozin", "Other: Glimepiride", "Drug: Placebo to Glimepiride", "Biological: Basal Insulin", "Drug: Metformin"]}, {"label": "Ertugliflozin 15 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.", "interventionNames": ["Drug: Ertugliflozin 15 mg", "Other: Glimepiride", "Drug: Placebo to Glimepiride", "Biological: Basal Insulin", "Drug: Metformin"]}, {"label": "Placebo/Glimepiride", "type": "PLACEBO_COMPARATOR", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Other: Glimepiride", "Biological: Basal Insulin", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.", "armGroupLabels": ["Ertuglifozin 5 mg"], "otherNames": ["MK-8835"]}, {"type": "DRUG", "name": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.", "armGroupLabels": ["Ertugliflozin 15 mg"], "otherNames": ["MK-8835"]}, {"type": "DRUG", "name": "Placebo to Ertugliflozin", "description": "Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.", "armGroupLabels": ["Ertuglifozin 5 mg", "Placebo/Glimepiride"]}, {"type": "OTHER", "name": "Glimepiride", "description": "Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertuglifozin 5 mg", "Placebo/Glimepiride"], "otherNames": ["Amaryl", "GLIMPID", "GLIMY"]}, {"type": "DRUG", "name": "Placebo to Glimepiride", "description": "Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertuglifozin 5 mg"]}, {"type": "BIOLOGICAL", "name": "Basal Insulin", "description": "Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertuglifozin 5 mg", "Placebo/Glimepiride"], "otherNames": ["Insulin glargine", "Insulin detemir", "NPH insulin", "Degludec"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin \\>=1500 mg/day, orally, once a day", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertuglifozin 5 mg", "Placebo/Glimepiride"], "otherNames": ["Glucophage XR", "Carbophage SR", "Riomet", "Fortamet", "Glumetza", "Obimet", "Gluformin", "Dianben", "Diabex", "Diaformin", "Siofor", "Metfogamma"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.", "timeFrame": "Up to Week 106"}, {"measure": "Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.", "timeFrame": "Up to Week 104"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "timeFrame": "Up to Week 26"}, {"measure": "Time to Glycemic Rescue Therapy at Week 26", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "timeFrame": "Week 26"}, {"measure": "Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 52"}, {"measure": "Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 52"}, {"measure": "Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "timeFrame": "Up to Week 52"}, {"measure": "Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 104"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 104"}, {"measure": "Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 104"}, {"measure": "Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104", "description": "Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "timeFrame": "Up to Week 104"}, {"measure": "Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 104"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 104"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 104"}, {"measure": "Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)", "description": "Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30"}, {"measure": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)", "description": "CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)", "description": "P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)", "description": "PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)", "description": "CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)", "description": "P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)", "description": "PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)", "description": "CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)", "description": "P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}, {"measure": "Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)", "description": "PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "timeFrame": "Baseline and Week 104"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of T2DM in accordance to American Diabetes Association guidelines\n* Participants must be receiving metformin monotherapy for less than 8 weeks prior to study participation or require change in their diabetes regimen to remain eligible to participate in the trial (including discontinuing anti-hyperglycemic agent \\[AHA\\] therapy) and must have a hemoglobin A1c of 7.0 to 10.5% (53-91 mmol/mol) after at least 8 weeks on a regimen of metformin monotherapy\n\nExclusion Criteria:\n\n* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation\n* A clinically significant electrocardiogram abnormality\n* A history of malignancy \u22645 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer\n* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor or glimepiride\n* On a blood pressure or lipid altering medication that have not been on a stable dose for at least 4 weeks prior to study participation\n* A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial\n* Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial\n* Pregnant or breast-feeding, or is expecting to conceive during the trial, including 14 days following the last dose of study drug", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "28857451", "type": "RESULT", "citation": "Rosenstock J, Frias J, Pall D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Erratum In: Diabetes Obes Metab. 2018 Nov;20(11):2708."}, {"pmid": "34213819", "type": "DERIVED", "citation": "Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2."}, {"pmid": "32648108", "type": "DERIVED", "citation": "Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9."}, {"pmid": "32372382", "type": "DERIVED", "citation": "Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5."}, {"pmid": "32324082", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13."}, {"pmid": "32324065", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13."}, {"pmid": "32236732", "type": "DERIVED", "citation": "Cherney DZI, Heerspink HJL, Frederich R, Maldonado M, Liu J, Pong A, Xu ZJ, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020 Jun;63(6):1128-1140. doi: 10.1007/s00125-020-05133-4. Epub 2020 Mar 31."}, {"pmid": "31797522", "type": "DERIVED", "citation": "Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3."}, {"pmid": "31064361", "type": "DERIVED", "citation": "Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7."}, {"pmid": "30614616", "type": "DERIVED", "citation": "Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019 Apr;21(4):1027-1036. doi: 10.1111/dom.13631. Epub 2019 Feb 14."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "FG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "FG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "207"}, {"groupId": "FG002", "numSubjects": "205"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "175"}, {"groupId": "FG001", "numSubjects": "187"}, {"groupId": "FG002", "numSubjects": "180"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "25"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Excluded Medication", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Non-Compliance With Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Participant moved", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "13"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized and treated participants", "groups": [{"id": "BG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "BG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "BG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "measures": [{"title": "Age, Continuous", "populationDescription": "All randomized and treated participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "56.5", "spread": "8.7"}, {"groupId": "BG001", "value": "56.6", "spread": "8.2"}, {"groupId": "BG002", "value": "56.9", "spread": "9.4"}, {"groupId": "BG003", "value": "56.6", "spread": "8.8"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "All randomized and treated participants", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "112"}, {"groupId": "BG003", "value": "333"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "97"}, {"groupId": "BG002", "value": "93"}, {"groupId": "BG003", "value": "288"}]}]}]}, {"title": "Race (NIH/OMB)", "populationDescription": "All randomized and treated participants", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "100"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "64"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "144"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "133"}, {"groupId": "BG003", "value": "411"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "46"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Baseline Hemoglobin A1C (A1C)", "description": "Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline A1C.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage A1C", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "207"}, {"groupId": "BG001", "value": "205"}, {"groupId": "BG002", "value": "202"}, {"groupId": "BG003", "value": "614"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.17", "spread": "0.90"}, {"groupId": "BG001", "value": "8.06", "spread": "0.89"}, {"groupId": "BG002", "value": "8.13", "spread": "0.93"}, {"groupId": "BG003", "value": "8.12", "spread": "0.90"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline FPG.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "202"}, {"groupId": "BG001", "value": "199"}, {"groupId": "BG002", "value": "203"}, {"groupId": "BG003", "value": "604"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "169.1", "spread": "41.7"}, {"groupId": "BG001", "value": "168.1", "spread": "45.5"}, {"groupId": "BG002", "value": "167.5", "spread": "44.4"}, {"groupId": "BG003", "value": "168.3", "spread": "43.8"}]}]}]}, {"title": "Body Weight", "populationDescription": "All randomized and treated participants who had a baseline Body Weight.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "84.5", "spread": "17.1"}, {"groupId": "BG001", "value": "84.8", "spread": "17.2"}, {"groupId": "BG002", "value": "85.3", "spread": "16.5"}, {"groupId": "BG003", "value": "84.9", "spread": "16.9"}]}]}]}, {"title": "Sitting Systolic Blood Pressure (SBP)", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline SBP.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "201"}, {"groupId": "BG001", "value": "201"}, {"groupId": "BG002", "value": "198"}, {"groupId": "BG003", "value": "600"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "129.30", "spread": "15.43"}, {"groupId": "BG001", "value": "130.48", "spread": "13.77"}, {"groupId": "BG002", "value": "130.37", "spread": "12.00"}, {"groupId": "BG003", "value": "130.05", "spread": "13.80"}]}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline DBP.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "201"}, {"groupId": "BG001", "value": "201"}, {"groupId": "BG002", "value": "198"}, {"groupId": "BG003", "value": "600"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "77.45", "spread": "7.55"}, {"groupId": "BG001", "value": "78.45", "spread": "8.32"}, {"groupId": "BG002", "value": "78.08", "spread": "7.45"}, {"groupId": "BG003", "value": "77.99", "spread": "7.78"}]}]}]}, {"title": "Bone Mineral Density (BMD) as Measured by Dual Energy X-Ray Absorptiometry (DXA) of the Femoral Neck", "description": "BMD at the femoral neck was assessed by DXA at baseline.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline BMD of the femoral neck.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/cm^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0.92", "spread": "0.17"}, {"groupId": "BG001", "value": "0.92", "spread": "0.16"}, {"groupId": "BG002", "value": "0.89", "spread": "0.15"}, {"groupId": "BG003", "value": "0.91", "spread": "0.16"}]}]}]}, {"title": "BMD as Measured by DXA of the Lumbar Spine (L1-L4)", "description": "BMD at the lumbar spine (L1-L4) was assessed by DXA at baseline.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline BMD of the lumbar spine (L1-L4).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/cm^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "204"}, {"groupId": "BG003", "value": "620"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1.15", "spread": "0.18"}, {"groupId": "BG001", "value": "1.13", "spread": "0.18"}, {"groupId": "BG002", "value": "1.10", "spread": "0.17"}, {"groupId": "BG003", "value": "1.13", "spread": "0.18"}]}]}]}, {"title": "BMD as Measured by DXA of the Total hip", "description": "BMD at the total hip was assessed by DXA at baseline.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline BMD of the total hip.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/cm^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1.06", "spread": "0.15"}, {"groupId": "BG001", "value": "1.07", "spread": "0.15"}, {"groupId": "BG002", "value": "1.04", "spread": "0.14"}, {"groupId": "BG003", "value": "1.06", "spread": "0.15"}]}]}]}, {"title": "BMD as Measured by DXA at the Distal Forearm", "description": "BMD at the distal forearm was assessed by DXA at baseline.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline BMD of the distal forearm.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/cm^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "205"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "619"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0.81", "spread": "0.14"}, {"groupId": "BG001", "value": "0.81", "spread": "0.14"}, {"groupId": "BG002", "value": "0.79", "spread": "0.13"}, {"groupId": "BG003", "value": "0.80", "spread": "0.14"}]}]}]}, {"title": "Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX)", "description": "CTX is a biochemical marker of bone resorption.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline CTX.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "200"}, {"groupId": "BG001", "value": "196"}, {"groupId": "BG002", "value": "195"}, {"groupId": "BG003", "value": "591"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "268.3", "spread": "132.9"}, {"groupId": "BG001", "value": "266.9", "spread": "129.9"}, {"groupId": "BG002", "value": "273.0", "spread": "135.2"}, {"groupId": "BG003", "value": "269.4", "spread": "132.5"}]}]}]}, {"title": "Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP)", "description": "P1NP is a biochemical marker of bone resorption.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline P1NP.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "microgm/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "200"}, {"groupId": "BG001", "value": "198"}, {"groupId": "BG002", "value": "198"}, {"groupId": "BG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "32.0", "spread": "15.0"}, {"groupId": "BG001", "value": "32.8", "spread": "14.5"}, {"groupId": "BG002", "value": "31.6", "spread": "16.5"}, {"groupId": "BG003", "value": "32.1", "spread": "15.3"}]}]}]}, {"title": "Bone Biomarker Parathyroid Hormone (PTH)", "description": "PTH is a biochemical marker of bone resorption.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline PTH.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "202"}, {"groupId": "BG001", "value": "194"}, {"groupId": "BG002", "value": "200"}, {"groupId": "BG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "19.29", "spread": "8.17"}, {"groupId": "BG001", "value": "19.52", "spread": "6.91"}, {"groupId": "BG002", "value": "19.97", "spread": "7.73"}, {"groupId": "BG003", "value": "19.59", "spread": "7.62"}]}]}]}, {"title": "Menopausal Status", "description": "Menopausal status includes men, premenopausal women, women who are perimenopausal or \\<3 years postmenopausal, women who are \u22653 years postmenopausal.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have menopausal status baseline information.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Male", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "97"}, {"groupId": "BG002", "value": "93"}, {"groupId": "BG003", "value": "288"}]}]}, {"title": "Premenopausal Women", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "49"}]}]}, {"title": "Perimenopausal or <3 yrs. postmen.", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "30"}]}]}, {"title": "Women \u22653 years postmenopausal", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "85"}, {"groupId": "BG003", "value": "254"}]}]}]}, {"title": "Estimated Glomerular Filtration Rate (eGFR)", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement of baseline eGFR.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73 m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "205"}, {"groupId": "BG003", "value": "621"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "91.6", "spread": "19.8"}, {"groupId": "BG001", "value": "88.9", "spread": "17.5"}, {"groupId": "BG002", "value": "91.1", "spread": "20.6"}, {"groupId": "BG003", "value": "90.5", "spread": "19.3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent A1C", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "lowerLimit": "-0.15", "upperLimit": "0.10"}, {"groupId": "OG001", "value": "-0.73", "lowerLimit": "-0.85", "upperLimit": "-0.61"}, {"groupId": "OG002", "value": "-0.91", "lowerLimit": "-1.03", "upperLimit": "-0.78"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.05", "ciUpperLimit": "-0.71", "otherAnalysisDescription": "Based on Constrained Longitudinal Data Analysis (cLDA) model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another anti-hyperglycemic agent, AHA), baseline eGFR (continuous), menopausal status. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.87", "ciUpperLimit": "-0.53", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another anti-hyperglycemic agent, AHA), baseline eGFR (continuous), menopausal status. Time was treated as a categorical variable."}]}, {"type": "PRIMARY", "title": "Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.", "populationDescription": "All participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to Week 106", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77.5"}, {"groupId": "OG001", "value": "70.5"}, {"groupId": "OG002", "value": "75.6"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.", "populationDescription": "All participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.4"}, {"groupId": "OG001", "value": "3.4"}, {"groupId": "OG002", "value": "3.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in % vs Placebo/Glimepiride", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.1", "ciUpperLimit": "5.4", "otherAnalysisDescription": "Miettinen \\& Nurminen method was used to construct the 95% CI"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in % vs Placebo/Glimepiride", "paramValue": "1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.5", "ciUpperLimit": "4.7", "otherAnalysisDescription": "Miettinen \\& Nurminen method was used to construct the 95% CI"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.85", "lowerLimit": "-5.93", "upperLimit": "4.23"}, {"groupId": "OG001", "value": "-27.54", "lowerLimit": "-32.36", "upperLimit": "-22.73"}, {"groupId": "OG002", "value": "-39.10", "lowerLimit": "-43.96", "upperLimit": "-34.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-38.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-44.50", "ciUpperLimit": "-31.99", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in the Least Squares Means", "paramValue": "-26.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.90", "ciUpperLimit": "-20.48", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.33", "lowerLimit": "-1.74", "upperLimit": "-0.92"}, {"groupId": "OG001", "value": "-3.01", "lowerLimit": "-3.40", "upperLimit": "-2.62"}, {"groupId": "OG002", "value": "-2.93", "lowerLimit": "-3.33", "upperLimit": "-2.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-1.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.16", "ciUpperLimit": "-1.03", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-1.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.24", "ciUpperLimit": "-1.11", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.8"}, {"groupId": "OG001", "value": "35.3"}, {"groupId": "OG002", "value": "40.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio Relative to Placebo", "paramValue": "4.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.64", "ciUpperLimit": "7.62", "otherAnalysisDescription": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), menopausal status, covariates for baseline A1C and baseline eGFR (continuous). Missing data imputed using a multiple imputation procedure based on cLDA prediction modeling with fixed effects as in the primary analysis, which allows for participants with missing data to be included in the analysis."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio Relative to Placebo", "paramValue": "3.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.81", "ciUpperLimit": "5.06", "otherAnalysisDescription": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), menopausal status, covariates for baseline A1C and baseline eGFR (continuous). Missing data imputed using a multiple imputation procedure based on cLDA prediction modeling with fixed effects as in the primary analysis, which allows for participants with missing data to be included in the analysis."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "lowerLimit": "-2.46", "upperLimit": "1.06"}, {"groupId": "OG001", "value": "-4.38", "lowerLimit": "-6.01", "upperLimit": "-2.75"}, {"groupId": "OG002", "value": "-5.20", "lowerLimit": "-6.87", "upperLimit": "-3.54"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-4.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.81", "ciUpperLimit": "-2.19", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.002", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-3.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.96", "ciUpperLimit": "-1.39", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "lowerLimit": "-0.85", "upperLimit": "1.31"}, {"groupId": "OG001", "value": "-1.59", "lowerLimit": "-2.59", "upperLimit": "-0.59"}, {"groupId": "OG002", "value": "-2.19", "lowerLimit": "-3.21", "upperLimit": "-1.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.001", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-2.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.86", "ciUpperLimit": "-0.98", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.013", "statisticalMethod": "Constrained Longitudinal Data Analysis", "paramType": "Difference in Least Squares Means", "paramValue": "-1.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.24", "ciUpperLimit": "-0.39", "otherAnalysisDescription": "Based on the cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who took at least one dose of study medication and had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.9"}, {"groupId": "OG001", "value": "8.7"}, {"groupId": "OG002", "value": "12.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "5.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.10", "ciUpperLimit": "13.90", "otherAnalysisDescription": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), menopausal status, covariates for baseline A1C and baseline eGFR (continuous). Missing data imputed using a multiple imputation procedure based on cLDA prediction modeling with fixed effects as in the primary analysis, which allows for participants with missing data to be included in the analysis."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.023", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "3.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.17", "ciUpperLimit": "8.22", "otherAnalysisDescription": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment, prior antihyperglycemic medication (metformin monotherapy or metformin + another AHA), menopausal status, covariates for baseline A1C and baseline eGFR (continuous). Missing data imputed using a multiple imputation procedure based on cLDA prediction modeling with fixed effects as in the primary analysis, which allows for participants with missing data to be included in the analysis."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "populationDescription": "All participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.7"}, {"groupId": "OG001", "value": "2.9"}, {"groupId": "OG002", "value": "1.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Miettinen & Nurminen method", "statisticalComment": "Miettinen \\& Nurminen method was used to construct both the 95% CI and derive p-value for the difference between the proportions (i.e. percentages).", "paramType": "Difference in % vs Placebo", "paramValue": "-16.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.2", "ciUpperLimit": "-11.2"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Miettinen & Nurminen method.", "statisticalComment": "Miettinen \\& Nurminen method was used to construct both the 95% CI and derive p-value for the difference between the proportions (i.e. percentages).", "paramType": "Difference in % vs Placebo", "paramValue": "-14.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.9", "ciUpperLimit": "-9.4"}]}, {"type": "SECONDARY", "title": "Time to Glycemic Rescue Therapy at Week 26", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "populationDescription": "All participants who received at least one dose of investigational product and received glycemic rescue through Week 26.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Days", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "105", "lowerLimit": "15", "upperLimit": "183"}, {"groupId": "OG001", "value": "112", "lowerLimit": "23", "upperLimit": "151"}, {"groupId": "OG002", "value": "139", "lowerLimit": "127", "upperLimit": "145"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent A1C", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}, {"groupId": "OG001", "value": "179"}, {"groupId": "OG002", "value": "173"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.99"}, {"groupId": "OG001", "value": "-0.72", "spread": "0.95"}, {"groupId": "OG002", "value": "-0.96", "spread": "0.88"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "173"}, {"groupId": "OG002", "value": "173"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.0", "spread": "40.0"}, {"groupId": "OG001", "value": "-22.4", "spread": "39.3"}, {"groupId": "OG002", "value": "-35.2", "spread": "40.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who received at least one dose of investigational product. Any participant without post-baseline data at Week 52 was assumed to be \"not at goal\", where goal was A1C \\<7%, for the calculation of the percentages.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.6"}, {"groupId": "OG001", "value": "34.8"}, {"groupId": "OG002", "value": "36.6"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who received at least one dose of investigational product. Any participant without post-baseline data at Week 52 was assumed to be \"not at goal\", where goal was A1C \\<6.5%, for the calculation of the percentages.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.0"}, {"groupId": "OG001", "value": "10.6"}, {"groupId": "OG002", "value": "14.6"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "populationDescription": "All participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.2", "lowerLimit": "12.37", "upperLimit": "23.04"}, {"groupId": "OG001", "value": "4.3", "lowerLimit": "2.01", "upperLimit": "8.09"}, {"groupId": "OG002", "value": "1.5", "lowerLimit": "0.3", "upperLimit": "4.22"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "181"}, {"groupId": "OG002", "value": "178"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "2.85"}, {"groupId": "OG001", "value": "-3.23", "spread": "3.68"}, {"groupId": "OG002", "value": "-3.35", "spread": "3.27"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "177"}, {"groupId": "OG002", "value": "173"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.65", "spread": "13.38"}, {"groupId": "OG001", "value": "-2.63", "spread": "14.40"}, {"groupId": "OG002", "value": "-4.28", "spread": "13.28"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "177"}, {"groupId": "OG002", "value": "173"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.38", "spread": "8.16"}, {"groupId": "OG001", "value": "-1.40", "spread": "9.60"}, {"groupId": "OG002", "value": "-1.19", "spread": "7.74"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent A1C", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "147"}, {"groupId": "OG002", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "0.93"}, {"groupId": "OG001", "value": "-0.60", "spread": "0.97"}, {"groupId": "OG002", "value": "-0.89", "spread": "0.90"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "143"}, {"groupId": "OG002", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.9", "spread": "44.3"}, {"groupId": "OG001", "value": "-18.2", "spread": "43.5"}, {"groupId": "OG002", "value": "-28.2", "spread": "44.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who received at least one dose of investigational product. Any participant without post-baseline data at Week 104 was assumed to be \"not at goal\", where goal was A1C \\<7%, for the calculation of the percentages.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.1"}, {"groupId": "OG001", "value": "24.6"}, {"groupId": "OG002", "value": "33.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who received at least one dose of investigational product. Any participant without post-baseline data at Week 104 was assumed to be \"not at goal\", where goal was A1C \\<6.5% for the calculation of the percentages.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.2"}, {"groupId": "OG001", "value": "10.6"}, {"groupId": "OG002", "value": "12.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104", "description": "Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.", "populationDescription": "All participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.4", "lowerLimit": "18.74", "upperLimit": "30.8"}, {"groupId": "OG001", "value": "11.1", "lowerLimit": "7.18", "upperLimit": "16.2"}, {"groupId": "OG002", "value": "10.7", "lowerLimit": "6.85", "upperLimit": "15.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "3.38"}, {"groupId": "OG001", "value": "-3.77", "spread": "4.29"}, {"groupId": "OG002", "value": "-3.63", "spread": "3.86"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "13.76"}, {"groupId": "OG001", "value": "-3.61", "spread": "12.78"}, {"groupId": "OG002", "value": "-3.13", "spread": "14.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "8.77"}, {"groupId": "OG001", "value": "-2.36", "spread": "9.23"}, {"groupId": "OG002", "value": "-1.52", "spread": "8.61"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)", "description": "Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "All subjects as treated (including those with all concentrations below the lower limit of quantification) were included in the calculation of the summary statistics. Numbers of participants with non-missing concentrations at the respective time points are displayed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "207"}, {"groupId": "OG002", "value": "205"}]}], "classes": [{"title": "Week 6:Pre-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "191"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Below the lower limit of quantification"}, {"groupId": "OG001", "value": "14.89", "spread": "28.11"}, {"groupId": "OG002", "value": "38.38", "spread": "74.83"}]}]}, {"title": "Week 12:Pre-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "196"}, {"groupId": "OG002", "value": "186"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Below the lower limit of quantification"}, {"groupId": "OG001", "value": "12.34", "spread": "26.07"}, {"groupId": "OG002", "value": "29.23", "spread": "55.63"}]}]}, {"title": "Week 12:60 mins post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "191"}, {"groupId": "OG002", "value": "179"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Below the lower limit of quantification"}, {"groupId": "OG001", "value": "74.84", "spread": "51.58"}, {"groupId": "OG002", "value": "228.13", "spread": "139.14"}]}]}, {"title": "Week 18:Pre-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "190"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.10"}, {"groupId": "OG001", "value": "9.91", "spread": "21.18"}, {"groupId": "OG002", "value": "24.46", "spread": "39.97"}]}]}, {"title": "Week 18:60 mins post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "198"}, {"groupId": "OG002", "value": "183"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.09"}, {"groupId": "OG001", "value": "74.39", "spread": "49.77"}, {"groupId": "OG002", "value": "214.96", "spread": "147.36"}]}]}, {"title": "Week 30:Pre-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "196"}, {"groupId": "OG002", "value": "187"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "1.07"}, {"groupId": "OG001", "value": "12.66", "spread": "25.50"}, {"groupId": "OG002", "value": "30.55", "spread": "60.33"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "lowerLimit": "-0.20", "upperLimit": "0.65"}, {"groupId": "OG001", "value": "-0.01", "lowerLimit": "-0.42", "upperLimit": "0.41"}, {"groupId": "OG002", "value": "0.12", "lowerLimit": "-0.31", "upperLimit": "0.55"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.71", "ciUpperLimit": "0.50", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.23", "ciPctValue": "97", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.83", "ciUpperLimit": "0.37", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "lowerLimit": "-0.89", "upperLimit": "0.09"}, {"groupId": "OG001", "value": "-0.10", "lowerLimit": "-0.57", "upperLimit": "0.38"}, {"groupId": "OG002", "value": "0.30", "lowerLimit": "-0.19", "upperLimit": "0.79"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.00", "ciUpperLimit": "1.39", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "0.99", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.63", "lowerLimit": "-0.92", "upperLimit": "-0.34"}, {"groupId": "OG001", "value": "-0.55", "lowerLimit": "-0.83", "upperLimit": "-0.27"}, {"groupId": "OG002", "value": "-0.36", "lowerLimit": "-0.65", "upperLimit": "-0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.15", "ciUpperLimit": "0.68", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.33", "ciUpperLimit": "0.48", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "-0.35", "upperLimit": "0.47"}, {"groupId": "OG001", "value": "-0.15", "lowerLimit": "-0.55", "upperLimit": "0.24"}, {"groupId": "OG002", "value": "-0.13", "lowerLimit": "-0.53", "upperLimit": "0.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.76", "ciUpperLimit": "0.39", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.78", "ciUpperLimit": "0.35", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)", "description": "CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 26.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}, {"groupId": "OG001", "value": "179"}, {"groupId": "OG002", "value": "180"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.8", "spread": "106.6"}, {"groupId": "OG001", "value": "51.9", "spread": "121.9"}, {"groupId": "OG002", "value": "80.2", "spread": "149.7"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)", "description": "P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 26.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "183"}, {"groupId": "OG002", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "11.7"}, {"groupId": "OG001", "value": "0.8", "spread": "12.1"}, {"groupId": "OG002", "value": "0.5", "spread": "15.0"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)", "description": "PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 26.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "182"}, {"groupId": "OG002", "value": "184"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.98", "spread": "6.71"}, {"groupId": "OG001", "value": "0.28", "spread": "7.52"}, {"groupId": "OG002", "value": "0.14", "spread": "7.53"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "lowerLimit": "-0.60", "upperLimit": "0.40"}, {"groupId": "OG001", "value": "-0.28", "lowerLimit": "-0.77", "upperLimit": "0.20"}, {"groupId": "OG002", "value": "0.07", "lowerLimit": "-0.43", "upperLimit": "0.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.53", "ciUpperLimit": "0.88", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.18", "ciPctValue": "97", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.88", "ciUpperLimit": "0.51", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.69", "lowerLimit": "-1.25", "upperLimit": "-0.14"}, {"groupId": "OG001", "value": "-0.49", "lowerLimit": "-1.04", "upperLimit": "0.06"}, {"groupId": "OG002", "value": "-0.44", "lowerLimit": "-1.06", "upperLimit": "0.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "0.98", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.51", "ciUpperLimit": "0.91", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "lowerLimit": "-1.19", "upperLimit": "-0.46"}, {"groupId": "OG001", "value": "-1.04", "lowerLimit": "-1.41", "upperLimit": "-0.67"}, {"groupId": "OG002", "value": "-1.32", "lowerLimit": "-1.69", "upperLimit": "-0.94"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.95", "ciUpperLimit": "-0.04", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.66", "ciUpperLimit": "0.23", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "lowerLimit": "-0.95", "upperLimit": "0.06"}, {"groupId": "OG001", "value": "-0.59", "lowerLimit": "-1.04", "upperLimit": "0.14"}, {"groupId": "OG002", "value": "-0.39", "lowerLimit": "-0.90", "upperLimit": "0.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.61", "ciUpperLimit": "0.72", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.78", "ciUpperLimit": "0.49", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)", "description": "CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.54", "spread": "43.34"}, {"groupId": "OG001", "value": "34.36", "spread": "52.74"}, {"groupId": "OG002", "value": "41.57", "spread": "50.69"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)", "description": "P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "179"}, {"groupId": "OG002", "value": "173"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.50", "spread": "120.29"}, {"groupId": "OG001", "value": "8.41", "spread": "30.95"}, {"groupId": "OG002", "value": "19.79", "spread": "79.57"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)", "description": "PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 52.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "171"}, {"groupId": "OG001", "value": "177"}, {"groupId": "OG002", "value": "175"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.11", "spread": "52.05"}, {"groupId": "OG001", "value": "11.09", "spread": "41.80"}, {"groupId": "OG002", "value": "2.48", "spread": "36.57"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "lowerLimit": "-0.47", "upperLimit": "0.66"}, {"groupId": "OG001", "value": "-0.19", "lowerLimit": "-0.72", "upperLimit": "0.35"}, {"groupId": "OG002", "value": "-0.13", "lowerLimit": "-0.68", "upperLimit": "0.42"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.01", "ciUpperLimit": "0.56", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.28", "ciPctValue": "97", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.06", "ciUpperLimit": "0.50", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.23", "lowerLimit": "-1.86", "upperLimit": "-0.61"}, {"groupId": "OG001", "value": "-1.11", "lowerLimit": "-1.74", "upperLimit": "-0.49"}, {"groupId": "OG002", "value": "-0.96", "lowerLimit": "-1.67", "upperLimit": "-0.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "1.13", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.70", "ciUpperLimit": "0.93", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.18", "lowerLimit": "-1.63", "upperLimit": "-0.73"}, {"groupId": "OG001", "value": "-1.72", "lowerLimit": "-2.19", "upperLimit": "-1.25"}, {"groupId": "OG002", "value": "-2.02", "lowerLimit": "-2.51", "upperLimit": "-1.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.44", "ciUpperLimit": "-0.24", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the least Squares Means", "paramValue": "-0.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.12", "ciUpperLimit": "0.05", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)", "description": "BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have a measurement at baseline and at least one post-baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "200"}, {"groupId": "OG002", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "lowerLimit": "-1.13", "upperLimit": "-0.03"}, {"groupId": "OG001", "value": "-0.40", "lowerLimit": "-0.87", "upperLimit": "0.06"}, {"groupId": "OG002", "value": "-0.64", "lowerLimit": "-1.19", "upperLimit": "-0.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.77", "ciUpperLimit": "0.65", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "paramType": "Difference in the Least Squares Means", "paramValue": "0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.50", "ciUpperLimit": "0.85", "otherAnalysisDescription": "Based on cLDA model with fixed effects for treatment, time, prior anti hyperglycemic medication (Metformin monotherapy or Metformin + another AHA), baseline eGFR (continuous), menopausal status, and the interaction of time by treatment. Time was treated as a categorical variable."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)", "description": "CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.29", "spread": "71.73"}, {"groupId": "OG001", "value": "26.94", "spread": "58.44"}, {"groupId": "OG002", "value": "32.53", "spread": "59.29"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)", "description": "P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "162"}, {"groupId": "OG002", "value": "162"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.38", "spread": "93.02"}, {"groupId": "OG001", "value": "10.11", "spread": "39.14"}, {"groupId": "OG002", "value": "24.21", "spread": "83.23"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)", "description": "PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.", "populationDescription": "All randomized participants who have received at least one dose of investigational product and have measurements of the respective endpoint at both baseline and Week 104.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 104", "groups": [{"id": "OG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}, {"id": "OG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "158"}, {"groupId": "OG002", "value": "161"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.12", "spread": "60.13"}, {"groupId": "OG001", "value": "8.16", "spread": "40.97"}, {"groupId": "OG002", "value": "5.46", "spread": "38.53"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 106 weeks", "description": "Participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or insulin glargine according to Investigator judgment. The analysis population was all participants who received at least one dose of investigational product. Adverse events were reported for the all post-randomization follow-up period.", "eventGroups": [{"id": "EG000", "title": "Placebo/Glimepiride", "description": "Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.", "deathsNumAffected": 3, "deathsNumAtRisk": 209, "seriousNumAffected": 22, "seriousNumAtRisk": 209, "otherNumAffected": 103, "otherNumAtRisk": 209}, {"id": "EG001", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.", "deathsNumAffected": 1, "deathsNumAtRisk": 207, "seriousNumAffected": 20, "seriousNumAtRisk": 207, "otherNumAffected": 79, "otherNumAtRisk": 207}, {"id": "EG002", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose \u2265110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.", "deathsNumAffected": 2, "deathsNumAtRisk": 205, "seriousNumAffected": 20, "seriousNumAtRisk": 205, "otherNumAffected": 100, "otherNumAtRisk": 205}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Myocardial bridging", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Phimosis", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Hypoacusis", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Duodenal ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Gastritis haemorrhagic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Haemorrhoidal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Osteomyelitis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Otitis media chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Limb crushing injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Intervertebral disc disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Necrotising myositis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Bowen's disease", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Hepatic cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Renal cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Stress urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Ureterolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Pulmonary fibrosis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Actinic keratosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 205}]}, {"term": "Aortic dissection", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 205}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Venous thrombosis limb", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Wound infection staphylococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}, {"term": "Traumatic intracranial haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 205}]}], "otherEvents": [{"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 13, "numAffected": 10, "numAtRisk": 205}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 44, "numAffected": 33, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 30, "numAffected": 23, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 22, "numAffected": 21, "numAtRisk": 205}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 13, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 22, "numAffected": 17, "numAtRisk": 205}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 21, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 16, "numAffected": 12, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 11, "numAffected": 9, "numAtRisk": 205}]}, {"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 15, "numAffected": 15, "numAtRisk": 205}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 213, "numAffected": 43, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 119, "numAffected": 14, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 66, "numAffected": 18, "numAtRisk": 205}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 12, "numAffected": 11, "numAtRisk": 205}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 20, "numAffected": 20, "numAtRisk": 205}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 10, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 18, "numAffected": 14, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 15, "numAffected": 11, "numAtRisk": 205}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 207}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 205}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the Sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2013-09-20", "uploadDate": "2018-06-20T08:55", "filename": "Prot_SAP_000.pdf", "size": 8026208}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Czech Republic", "Hong Kong", "Hungary", "Israel", "Mexico", "Poland", "Romania", "Russian Federation", "Slovakia", "South Africa", "Taiwan", "United Kingdom", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000069057", "term": "Insulin Detemir"}, {"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M349", "name": "Insulin Detemir", "asFound": "Oocyte", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M327", "name": "Isophane Insulin, Human", "relevance": "LOW"}, {"id": "M10373", "name": "Insulin, Isophane", "relevance": "LOW"}, {"id": "M173174", "name": "Isophane insulin, beef", "relevance": "LOW"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}